4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes

NCT00558571 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

78

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: BI 10773 low dose
DRUG: placebo to BI 10773
DRUG: BI 10773 medium dose
DRUG: BI 10773 high dose

Sponsor

Boehringer Ingelheim